ACURATE neo2 vs. TAVR: Aortic Stenosis Trial Results
- Patients with symptomatic severe aortic stenosis who underwent transcatheter aortic valve replacement (TAVR) using the ACURATE neo2 valve experienced significantly poorer outcomes compared to those receiving commercial valves,according...
- The study's primary endpoint, a composite of all-cause mortality, all stroke, and rehospitalization at one year, was significantly worse in the ACURATE neo2 group.
- Further research is needed to understand the reasons behind the poorer outcomes associated with the ACURATE neo2 valve and to determine the best course of action for patients...
A critical study reveals troubling outcomes for patients undergoing TAVR with the ACURATE neo2 valve. The research indicates that this valve leads to substantially worse results in patients with severe aortic stenosis compared to other commercial valves. Specifically, the ACURATE neo2 group experienced higher rates of mortality, stroke, and rehospitalization within a year, underscoring concerns about its efficacy. This pivotal trial, comparing ACURATE neo2 against established alternatives, prompts a reevaluation of current TAVR practices. News Directory 3 is closely monitoring these developments. Discover what’s next for the future of transcatheter aortic valve replacement and the treatment of aortic stenosis.
ACURATE neo2 TAVR Linked to Worse Outcomes in Aortic Stenosis Patients
Updated June 8,2025
Patients with symptomatic severe aortic stenosis who underwent transcatheter aortic valve replacement (TAVR) using the ACURATE neo2 valve experienced significantly poorer outcomes compared to those receiving commercial valves,according to a recent study. The ACURATE neo2 failed to demonstrate non-inferiority in the trial.
The study’s primary endpoint, a composite of all-cause mortality, all stroke, and rehospitalization at one year, was significantly worse in the ACURATE neo2 group. This raises concerns about the use of this particular valve in TAVR procedures.
What’s next
Further research is needed to understand the reasons behind the poorer outcomes associated with the ACURATE neo2 valve and to determine the best course of action for patients with severe aortic stenosis needing TAVR. The findings may influence future guidelines and clinical practice in the treatment of aortic stenosis.